Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.40 |
| ▸ | F13A1 | P00488 | 4/20 | 0.39 |
| ▸ | TGM1 | P22735 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140333 | 1.00 | HTT (0.40) | HTTNPY5RF13A1TGM1MEN1 | |
| SCHEMBL4135320 | 0.89 | KMT2A (0.39) | HTTMEN1KMT2AUSP2BDKRB1 | |
| SCHEMBL4135313 | 0.89 | KMT2A (0.39) | HTTMEN1KMT2AUSP2BDKRB1 | |
| SCHEMBL4129723 | 0.84 | TRPV4 (0.39) | MEN1KMT2APKMBDKRB1 | |
| SCHEMBL4129734 | 0.84 | TRPV4 (0.39) | MEN1KMT2APKMBDKRB1 | |
| SCHEMBL4135071 | 0.84 | TRPV4 (0.39) | MEN1KMT2APKMBDKRB1 | |
| SCHEMBL4145496 | 0.83 | NPY5R (0.48) | HTTNPY5RF13A1TGM1MEN1 | |
| SCHEMBL4148627 | 0.82 | BMP1 (0.37) | MEN1KMT2AUSP2PKMALDH1A1 | |
| SCHEMBL4768084 | 0.82 | MEN1 (0.37) | HTTMEN1KMT2AUSP2ALDH1A1 | |
| SCHEMBL4148621 | 0.82 | BMP1 (0.37) | MEN1KMT2AUSP2PKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | HTT 1977/4885NPY5R 298/4885F13A1 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.